OXILAN-300
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXILAN-300 is a small-molecule injectable product approved by Guerbet in December 1995 for an unspecified indication. The mechanism of action and pharmacologic class are not publicly documented in available data. Based on the brand name and injection route, it may be a contrast agent or diagnostic imaging product.
LOE Approaching
Product is nearing loss of exclusivity with moderate competitive pressure (30%), indicating defensive commercial strategy and likely small, specialized teams focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OXILAN-300 currently shows zero linked job openings, reflecting its mature, LOE-approaching status. Career growth on this product is limited; roles are primarily defensive commercial positions focused on market maintenance and competitive response rather than expansion or innovation.
Brand ManagerCommercial Strategy Lead
Worked on OXILAN-300 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.